Virtual Cell Models, Tahoe-100 and Data for AI-in-Bio with Vevo Therapeutics and the Arc Institute

On this week’s episode of No Priors, Sarah Guo is joined by leading members of the teams at Vevo Therapeutics and the Arc Institute – Nima Alidoust, CEO/Co-Founder at Vevo Therapeutics; Johnny Yu, CSO/Co-Founder at Vevo Therapeutics; Patrick Hsu, CEO/Co-Founder at Arc Institute; Dave Burke, CTO at Arc Institute; and Hani Goodarzi, Core Investigator at Arc Institute. Predicting protein structure (AlphaFold 3, Chai-1, Evo 2) was a big AI/biology breakthrough. The next big leap is modeling entire human cells—how they behave in disease, or how they respond to new therapeutics. The same way LLMs needed enormous text corpora to become truly powerful, Virtual Cell Models need massive, high-quality cellular datasets to train on. In this episode, the teams discuss the groundbreaking release of the Tahoe-100M single cell dataset, Arc Atlas, and how these advancements could transform drug discovery. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @Nalidoust | @IAmJohnnyYu | @PDHsh | @Davey_Burke | @Genophoria Download the Tahoe Dataset Show Notes: 0:00 Introduction 1:40 Significance of Tahoe-100M dataset 4:22 Where we are with virtual cell models and protein language models 10:26 Significance of perturbational data 17:39 Challenges and innovations in data collection 24:42 Open sourcing and community collaboration 33:51 Predictive ability and importance of virtual cell models 35:27 Drug discovery and virtual cell models 44:27 Platform vs. single hypothesis companies 46:05 Rise of Chinese biotechs 51:36 AI in drug discovery

Om Podcasten

At this moment of inflection in technology, co-hosts Elad Gil and Sarah Guo talk to the world's leading AI engineers, researchers and founders about the biggest questions: How far away is AGI? What markets are at risk for disruption? How will commerce, culture, and society change? What’s happening in state-of-the-art in research? “No Priors” is your guide to the AI revolution. Email feedback to show@no-priors.com. Sarah Guo is a startup investor and the founder of Conviction, an investment firm purpose-built to serve intelligent software, or "Software 3.0" companies. She spent nearly a decade incubating and investing at venture firm Greylock Partners. Elad Gil is a serial entrepreneur and a startup investor. He was co-founder of Color Health, Mixer Labs (which was acquired by Twitter). He has invested in over 40 companies now worth $1B or more each, and is also author of the High Growth Handbook.